Skip Navigation

Annals of Oncology 2007 18(7):1281; doi:10.1093/annonc/mdm273
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carmona-Bayonas, A
Right arrow Articles by Díaz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carmona-Bayonas, A
Right arrow Articles by Díaz, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

letters to the editor

Tailored hormonal therapy in secretory adrenocortical cancer

The first 10% of the full text of this article appears below.

Mitotane is often considered the front-line hormonal therapy of adrenocortical carcinoma (ACC). An illustrative case concerning this issue and the rationale to ponder other alternatives is reported. A 69 year-old woman, diagnosed with ACC was admitted with hypertensive crisis, supraventricular tachycardia, congestive heart-failure, diarrhoea and rabdomyolisis. Two years earlier, she had undergone . . . [Full Text of this Article]

A Carmona-Bayonas1, IO Soler2, FI Gómez2, EG Billalabeitia1, HP Saura2, MSA Tafalla2 and MP Díaz2

1 Medical Oncology-Haematology Department
2 Endocrinology Department, Hospital Universitario Morales Meseguer, Murcia, Spain

(*E-mail: trebla_albert@hotmail.com)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?